{"id":"NCT00463567","sponsor":"Novartis","briefTitle":"26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","officialTitle":"A 26-week Treatment, Multicenter, Randomized, Double Blind, Double Dummy, Placebo-controlled, Adaptive, Seamless, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of Two Doses of Indacaterol (Selected From 75, 150, 300 & 600 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease Using Blinded Formoterol (12 µg b.i.d.) and Open Label Tiotropium (18 µg o.d.) as Active Controls","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2007-04","primaryCompletion":"2008-08","completion":"2008-08","firstPosted":"2007-04-20","resultsPosted":"2011-08-18","lastUpdate":"2011-08-18"},"enrollment":2059,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Disease, Chronic Obstructive","COPD","Lung Diseases, Obstructive"],"interventions":[{"type":"DRUG","name":"Indacaterol","otherNames":[]},{"type":"DRUG","name":"Formoterol (12 µg b.i.d.)","otherNames":[]},{"type":"DRUG","name":"Tiotropium (18 µg o.d.)","otherNames":[]},{"type":"DRUG","name":"Placebo to Indacaterol","otherNames":[]},{"type":"DRUG","name":"Placebo to Formoterol","otherNames":[]}],"arms":[{"label":"Indacaterol 150 µg (Continued Into Stage 2)","type":"EXPERIMENTAL"},{"label":"Indacaterol 300 µg (Continued Into Stage 2)","type":"EXPERIMENTAL"},{"label":"Tiotropium 18 µg (Continued Into Stage 2)","type":"ACTIVE_COMPARATOR"},{"label":"Placebo (Continued Into Stage 2)","type":"PLACEBO_COMPARATOR"},{"label":"Indacaterol 75 µg (Not Continued into Stage 2)","type":"EXPERIMENTAL"},{"label":"Indacaterol 600 µg (Not Continued Into Stage 2)","type":"EXPERIMENTAL"},{"label":"Formoterol 12 µg (Not Continued Into Stage 2)","type":"ACTIVE_COMPARATOR"}],"summary":"Stage 1 of the study is designed to provide data about the risk-benefit of 4 dose regimens of indacaterol (75, 150, 300 \\& 600 µg o.d.) in order to select two doses to carry forward into study Stage 2. Study Stage 2 will provide pivotal confirmation of efficacy, safety, and tolerability of the selected indacaterol doses in patients with COPD","primaryOutcome":{"measure":"Trough Forced Expiratory Volume in 1 Second (FEV1) Assessed by Spirometry 24 Hour Post Dose After 12 Weeks of Treatment","timeFrame":"after 12 weeks of treatment","effectByArm":[{"arm":"Indacaterol 150 µg (Continued Into Stage 2)","deltaMin":1.46,"sd":0.015},{"arm":"Indacaterol 300 µg (Continued Into Stage 2)","deltaMin":1.46,"sd":0.015},{"arm":"Tiotropium 18 µg (Continued Into Stage 2)","deltaMin":1.42,"sd":0.015},{"arm":"Placebo (Continued Into Stage 2)","deltaMin":1.28,"sd":0.015}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":16},"locations":{"siteCount":344,"countries":["United States","Argentina","Canada","Germany","India","Italy","Puerto Rico","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)"]},"refs":{"pmids":["22206353","22158330","21397482","21227674","20463178"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":35,"n":416},"commonTop":["Chronic obstructive pulmonary disease","Nasopharyngitis","Upper respiratory tract infection","Cough","Headache"]}}